Antiemetic claims for glutathione backed by phase III trial

Claims that glutathione is able to ameliorate the toxicity of cisplatin are firmly supported by the results of a double-blind, phase III, randomised trial. This is the first phase III trial to test glutathione's antiemetic efficacy against cisplatin. Neurotoxicity in women with ovarian cancer was significantly reduced by glutathione compared with placebo. The results were presented at the European Society for Medical Oncology [Lisbon, Portugal; November 1994].